Tools   Select Another Resource Report Type

http://www.bioon.com/bioline/neurosci/course/index.htm

An illustrated guide to the essential basics of clinical neuroscience created in conjunction with the first-year course for medical students.
Topics covered:
* Coronal and horizontal sections
* Basic visual pathway
* Basic somatosensory pathway
* Basic motor pathway
* Eye and retina
* Central visual pathways
* Auditory and vestibular systems
* Somatosensory pathways from the body
* Somatosensory pathways from the face
* Spinal motor structures
* Brainstem nuclei of cranial nerves
* Basal ganglia and cerebellum
* Hypothalamus and autonomic nervous system
* Medial temporal lobe and memory
* Sleep and language
* Where is...?

Proper citation: Washington University School of Medicine Neuroscience Tutorial (RRID:SCR_002271) Copy   

•   Source: SciCrunch Registry

http://www.humgen.rwth-aachen.de/

Catalog of all changes detected in PKHD1 (Polycystic Kidney and Hepatic Disease 1) in a locus specific database. Investigators are invited to submit their novel data to this database. These data should be meaningful for clinical practice as well as of relevance for the reader interested in molecular aspects of polycystic kidney disease (PKD). There are also some links and information for ARPKD patients and their parents. Autosomal recessive polycystic kidney disease (ARPKD/PKHD1) is an important cause of renal-related and liver-related morbidity and mortality in childhood. This study reports mutation screening in 90 ARPKD patients and identifies mutations in 110 alleles making up a detection rate of 61%. Thirty-four of the detected mutations have not been reported previously. Two underlying mutations in 40 patients and one mutation in 30 cases are disclosed, and no mutation was detected on the remaining chromosomes. Mutations were found to be scattered throughout the gene without evidence of clustering at specific sites. PKHD1 mutation analysis is a powerful tool to establish the molecular cause of ARPKD in a given family. Direct identification of mutations allows an unequivocal diagnosis and accurate genetic counseling even in families displaying diagnostic challenges.

Proper citation: Autosomal Recessive Polycystic Kidney Disease Mutation Database (RRID:SCR_002290) Copy   

•   Source: SciCrunch Registry

http://www.cpdd.vcu.edu/

The College on Problems of Drug Dependence (CPDD) is an interdisciplinary research society whose members address problems of drug dependence in the broadest range of scientific disciplines, including chemistry, basic biology, pharmacology, behavioral science, clinical research, sociology, psychology, anthropology, and history. CPDD serves as an interface among governmental, industrial and academic communities maintaining liaisons with regulatory and research agencies as well as educational, treatment, and prevention facilities in the drug abuse field. It also functions as a collaborating center of the World Health Organization. The Annual Scientific Meeting: Since 1938, a major focus of the CPDD's activities has been its sponsorship of an annual scientific meeting. This conference serves as a forum bringing together basic scientists and clinical investigators from industry, academia, and government. Representatives of regulatory agencies, as well as scientists and professionals in a number of diverse disciplines interested in the biochemical, behavioral, and public health aspects of drug dependence participate. Special Conferences: Periodically, the College sponsors conferences focused on timely topics of interest to researchers, government, industry, and the public. In recent years, CPDD has organized meetings on Abuse Liability Assessment of CNS Drugs; Drug Formulation and Abuse Liability; Pre-Clinical Abuse Liability Testing; Women and Smoking: Understanding Socioeconomic Influences; and Risk Management and Post-Marketing Surveillance for CNS-Acting Drugs. Consultation Activities: The CPDD provides consulting expertise in the area of epidemiology, treatment, prevention, and all the basic and clinical sciences related to drug dependence, drug abuse, and their behavioral and medical consequences. Sponsorship of Drug and Alcohol Dependence: The CPDD sponsors the journal Drug and Alcohol Dependence, published by Elsevier. A principal goal of the journal is to provide a source of quality, timely reports of scientific advances in substance abuse research. The journal is international in scope and interdisciplinary in coverage. The CPDD invites contributors. Donations Tax-deductible donations can be made to CPDD to support the Annual Scientific Meeting, testing facilities, drug assessment activities and Awards for Excellence.

Proper citation: College on Problems of Drug Dependence (RRID:SCR_002618) Copy   

•   Source: SciCrunch Registry

http://selectscience.net

SelectScience.net is a leading online resource for applied chemists, clinical chemists and life scientists. It provides up-to-date product and industry news, an extensive product directory and end-user product reviews, as well as the ability for visitors to review the products they use. Scientists can also use the site to search for jobs, application notes and scientific conferences. Sponsors: The company is run by independent scientists and funded from Government and Corporate sponsorship.

Proper citation: SelectScience (RRID:SCR_002733) Copy   

•   Source: SciCrunch Registry

http://www.wanprc.org/

Center that aims to provide an environment to support biomedical research directed towards human health issues and nonhuman primate health and biology. To meet this mission, the WaNPRC supports biomedical research activities, professional research staff, specifically bred and maintained nonhuman primate colonies, and dedicated facilities and equipment required for nonhuman primate research protocols.

Proper citation: Washington National Primate Research Center (RRID:SCR_002761) Copy   

•   Source: SciCrunch Registry

http://www.drugabuseresearchtraining.org/

THIS RESOURCE IS NO LONGER IN SERVICE, documented on November 07, 2012. Decemeber 15, 2011 - Thank you for your interest in DrugAbuseResearchTraining.org. The site, courses, and resources are no longer available. Please send an email to inquiry (at) md-inc.com if you would like to be notified if the site or courses become available again. Introduction to Clinical Drug and Substance Abuse Research Methods is an online training program intended to introduce clinicians and substance abuse professionals to basic clinical research methods. The program is divided into four modules. Each module covers an entire topic and includes self-assessment questions, references, and online resources: * The Neurobiology of Drug Addiction * Biostatistics for Drug and Substance Abuse Research * Evaluating Drug and Substance Abuse Programs * Designing and Managing Drug and Substance Abuse Clinical Trials The learning objectives of this program are to help you: * Evaluate the benefits of alternative investigative approaches for answering important questions in drug abuse evaluation and treatment. * Define the proper levels of measurement and appropriate statistical methods for a clinical study. * Address common problems in data collection and analysis. * Anticipate key human subjects and ethical issues that arise in drug abuse studies. * Interpret findings from the drug abuse research literature and prepare a clinical research proposal. * Prepare research findings for internal distribution or publication in the peer reviewed literature. * Recognize drug addiction as a cyclical, chronic disease. * Understand and describe the brain circuits that are affected by addicting drugs, and explain to others the effects of major classes of addicting drugs on brain neurotransmitters. * Utilize new pharmacologic treatments to manage persons with drug addiction. Physicians can earn AMA PRA Category 1 Credit and purchase a high resolution printable electronic CME certificate(view sample); non-physicians can purchase high resolution printable electronic certificate of course participation that references AMA PRA Category 1 credit (view sample). This program does not offer printed certificates.

Proper citation: Online Education for the International Research Community: AboutIntroduction to Clinical Drug and Substance Abuse Research Methods (RRID:SCR_000802) Copy   

•   Source: SciCrunch Registry

http://www2.gsu.edu/~wwwvir/index.html

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on August 18,2025. The National B Virus Resource Center is located in the Viral Immunology Center of Georgia State Universitys Department of Biology. Their laboratory is studying viruses that directly affect the central nervous system of infected hosts. Current projects in the laboratory are focused on the molecular biology of human and nonhuman primate alphaherpesviruses and the diseases they cause, immune response characterization, antiviral strategies, including drug discovery and high-throughput drug screening within unique, high containment laboratory suites. They are also actively engaged in the study of unique reoviruses that have the capacity to infect the central nervous systems of non human primates, langur viruses, and a newly isolated mangaby herpesvirus. Alphaherpesviruses target the central nervous system of susceptible hosts, and subsequently establish latent infections generally without severely damaging the host. There may be an initial acute phase when the virus successfully replicates in peripheral tissue of the host. This replication, when it occurs, induces a series of specific immune functions that can serve as markers of infection. We use these markers to design, develop and implement diagnostic assays that will be useful during the management of clinical disease. Each herpesvirus coexists peacefully with the natural host in which it has co-evolved, but when the viruses for any reason find themselves no longer in the natural host, the usual host:parasite relationship may change dramatically. In some closely related hosts the virus can replicate and, in some cases, pathogenesis of the infection is radically more severe than that which occurs in the natural host. For example, this can be seen when New World monkeys are infected with humans herpesviruses, e.g., HSV-1 or HSV-2, or when humans are infected with B virus from a macaque, a member of the Old World monkey family. Their studies focus on the mechanisms by which virus kills the host and how that process can be circumvented with early identification, appropriate antiviral drugs, and in the future, effective vaccines. We continually screen the efficacy of existing as well as novel antiviral agents to inhibit the growth of viruses that can potentially cross into the human population, either through occupational exposure or through more subtle contact. Their laboratory provides a global resource funded by National Institutes of Healths National Center for Research Resources to assist in the identification of zoonotic disease transmissions and develop enhanced strategies to detect virus in macaques. They particularly focus on the transmission of B virus from Asian monkeys to humans who come in contact with them. Members of the genus Macaca include rhesus monkeys, cynomolgus macaques, snow macaques, as well as all other macaques. If the macaque is in the midst of the acute or recurrent infection with B, virus can be transmitted to people who handle these monkeys through cuts, scratches, splashes, bites, or even contaminated equipment or surfaces, i.e., fomites. To counter the effects of this virus, the NIH and Centers for Disease Control and Prevention have instituted a critical set of guidelines for institutions to follow in the event of exposures. Their laboratory provides immediate support to these cases to assist in the rapid diagnosis of B virus infections and to determine the efficacy of selected treatment. Lifetime patient monitoring is provided to identify possible reactivation disease and to better track this unique herpesvirus as it has begun its existence in the human populations. Sponsors: The viral immunology center is funded by National Institutes of Healths National Center for Research Resources.

Proper citation: Viral Immunology Center (RRID:SCR_001089) Copy   

•   Source: SciCrunch Registry

https://medschool.vanderbilt.edu/pharmacology/

At the Department of Pharmacology at Vanderbilt University Medical Center we engage in scientific discovery to elucidate biological mechanisms and develop novel therapeutics. We provide training focused on critical thinking to promote innovation, scholarship and integrity. To this end, we foster creativity, collegiality, and leadership. The Department is one of the most distinguished Pharmacology departments in the country and have placed in the top two NIH ranking positions for sixteen of the last twenty years. Research interests in the Department include five major areas: signal transduction, neuroscience, bioactive lipid metabolism, genetic basis of cardiovascular dysfunction, and drug metabolism. Molecules under investigation include G-protein coupled receptors (rhodopsin, adrenergic, serotonin and receptors), heterotrimeric G-proteins, ion channels, transporters and regulatory proteins such as arrestins, protein kinases and protein phosphatases. A strength in our research and training environment is that Vanderbilt University has a world-acclaimed Division of Clinical Pharmacology, which links the Department of Medicine with the Department of Pharmacology. Faculty members in the Division of Clinical Pharmacology focus on human disease and clinical enigmas as the origin of their questions for research. Basic scientists who pursue their inquiries in this environment are continually informed by their colleagues of the pathophysiological and potential therapeutic relevance that can be achieved by appropriate focus of their efforts. We have created one of the first programs in the country to answer the call from the National Institutes of Health (NIH) for more scientists trained in the area of drug discovery and development. A unique feature of the department is our outstanding Ph.D. training program. Almost 60 scientists in training are addressing important issues in fields such neuroscience, cardiovascular development, receptor signaling, and drug metabolism. Scientists in these areas are linked by a common interest in, and understanding of, the basic principles of drug action and design. This perspective makes our trainees ideally suited for a wide range of careers and our program is committed to developing leaders in academia, industry, and regulatory affairs. Postdoctoral and other positions are available.

Proper citation: Vanderbilt University Medical Center Pharmacology (RRID:SCR_001450) Copy   

•   Source: SciCrunch Registry

http://www.pd-doc.org/

THIS RESOURCE IS NO LONGER IN SERVICE, documented on December 02, 2011. Notice: This domain name expired on 10/29/11 and is pending renewal or deletion PD-DOC is a portal and a database resource, hosting a database and linking to other databases and data sets of clinical and translational data. PD-DOC functions to organize and facilitate clinical and translational research in Parkinson's disease. The PD-DOC Database contains standardized data collected by user institutions on large numbers of patients with Parkinsons disease and other parkinsonian disorders. In some cases, data is obtained at a single point in time, while in others data is collected repeatedly over time. The PD-DOC Database is composed of the Core Data Set (CDS) which consists of those variables required to be gathered for each subject whose data is entered into the PD-DOC database. In 2005, working groups of Udall Center and invited experts deliberated to establish the components of each CDS section (e.g. General Clinical, Cognitive/Behavioral, Postmortem Brain Neuropathological Findings). The PD-DOC CDS was established and designed to optimize data analyses and data mining for large numbers of subjects participating in a variety of research studies. In most cases corresponding DNA samples are available form the NINDS Human Genetic Repository (at Coriell). Much of the website is publicly available for viewing. To request access to sections of the website dealing with downloading or requesting data, requesting a consultation, or submitting data or other information you will need to register. Before registering, you should read the PD-DOC Policies. Note that PD-DOC data can be used for research purposes only. Once your registration is successfully completed you will be automatically logged into the website.

Proper citation: PD-DOC (RRID:SCR_001596) Copy   

•   Source: SciCrunch Registry

https://edic.bsc.gwu.edu

Publications from a multi-center, longitudinal, observational study examining the risk factors associated with the long-term complications of type 1 diabetes. The study began in 1994 and follows the 1441 participants previously enrolled in the Diabetes Control and Complications Trial (DCCT), http://diabetes.niddk.nih.gov/dm/pubs/control/index.aspx. The primary aim of EDIC is to examine the long-term effects of conventional vs. intensive diabetes treatment received during the DCCT on the subsequent development and progression of microvascular, neuropathic and cardiovascular complications. This involves studying the influence of genetic factors and other factors such as HbA1c, blood pressure, lipid levels, and treatment modalities on the development and progression of these complications. Annual or biennial measurements (using DCCT methods, standardized protocols and central laboratories) of vascular events, albumin excretion, GFR, ECG, ankle-brachial BP index, serum lipids and HbA1c allows the following analyses: 1) continuation of intention-to-treat analyses to determine long-term effects of prior separation of glycemic levels; 2) risk factors for macrovascular outcomes; 3) correlation of progression of micro- and macrovascular outcomes. The current updated version of the EDIC Protocol is available for download. EDIC is made up of 28 clinical centers, one data coordinating center and one clinical coordinating center.

Proper citation: Epidemiology of Diabetes Interventions and Complications (RRID:SCR_001468) Copy   

•   Source: SciCrunch Registry

https://clinicaltrials.gov/study/NCT01619475

Study consisting of nine liver transplant centers with expertise in adult living-donor liver transplantation (LDLT) and a central data coordinating center to provide valuable information on the outcomes of adult to adult living donor liver transplantation (AALDLT) to aid decisions made by physicians, patients, and potential donors. The study will establish and maintain the infrastructure required to accrue and follow sufficient numbers of patients being considered for and undergoing AALDLT to provide generalizable data from adequately powered studies. The major aims of A2ALL are as follows: * Quantify the impact of choosing LDLT on the candidate for transplantation * Characterize the difference between LDLT and deceased donor liver transplant (DDLT) in terms of post-transplant outcomes, including patient and graft survival, surgical morbidity, and resource utilization on the recipient of a transplant * Determine the short- and long-term health and quality of life (QOL) impact of donation, including (a) morbidity after liver donation and (b) long-term health-related QOL of donors. * Standardize and assess the role of informed consent in affecting the decision to donate and satisfaction after living liver donation * Other aims include comparison of the severity of recurrence of hepatocellular carcinoma for DDLT versus LDLT, the systematic characterization of liver regeneration and function in donors and recipients, the evaluation of the differences in the immune response to LDLT versus DDLT, and the establishment of a robust data and sample repository on liver transplantation that may be used to study clinical and biological questions as new technologies and resources become available. Patients enrolled in the study will be followed and managed in a standardized fashion.

Proper citation: Adult to Adult Living Donor Liver Transplantation Cohort Study (RRID:SCR_001494) Copy   

•   Source: SciCrunch Registry

https://repository.niddk.nih.gov/study/119

Multi-center randomized clinical trial to determine if the addition of behavioral treatment to drug therapy for the treatment of urge incontinence will make it possible to discontinue the drug and still maintain a reduced number of accidents. The most popular treatments for urge incontinence are drug therapy and behavior therapy, each with its own limitations. In this clinical study, the Urinary Incontinence Treatment Network (UITN) aims to determine differences with the addition of behavioral treatment to drug therapy alone.

Proper citation: Behavior Enhances Drug Reduction of Incontinence (RRID:SCR_001495) Copy   

•   Source: SciCrunch Registry

http://pathology-anatomy.missouri.edu/research/diabetes.html

Standardization of c-peptide by calibrating C-peptide measurement to a reference method can increase comparability between laboratories. The C-peptide standardization program is supported to establish reliability in results and facilitate the conduct of international clinical trials. For c-peptide, purified or processed material shows significant matrix effects and cannot be used for calibration. The C-peptide program has evaluated the use of single donor and pooled specimens for use by manufacturers in the calibration of these assays and determined that this strategy will reduce C-peptide variability among different assay methods. The standardization process through manufacturer re-calibration is ongoing.

Proper citation: Standardization of C-peptide measurements (RRID:SCR_001499) Copy   

•   Source: SciCrunch Registry

http://drcrnet.jaeb.org/

A collaborative network to facilitate multicenter clinical research of diabetic retinopathy, diabetic macular edema and associated conditions. It supports the identification, design, and implementation of multicenter clinical research initiatives focused on diabetes-induced retinal disorders. Principal emphasis is placed on clinical trials, but epidemiologic outcomes and other research may be supported as well. It currently includes over 109 participating sites (offices) with over 320 physicians throughout the United States. Closed and active studies are listed along with the associated protocols, public datasets, and publications.

Proper citation: Diabetic Retinopathy Clinical Research Network (RRID:SCR_001514) Copy   

•   Source: SciCrunch Registry

http://dc-research.eu/

An open knowledge resource for the dendritic cell research community, this index of research assets and expertise is designed to support translational research by providing annotations and interrelations on materials, datasets, tools, techniques, persons and organizations. The content of DC-RESEARCH.EU can be accessed by researchers through its website and can be accessed programmatically: the information in DC-RESEARCH.EU is represented through machine processable languages, proper of the Semantic Web (RDF and RDFa). To submit to the dc-thera directory please contact: dc-research_at_leafbioscience.com

Proper citation: DC-Research.eu - Dendritic Cell Research Knowledge Portal (RRID:SCR_004200) Copy   

•   Source: SciCrunch Registry

http://www.brainnet-europe.org/

THIS RESOURCE IS NO LONGER IN SERVICE.Documented on July 7, 2022. Consortium of 19 brain banks across Europe with an aim to harmonize neuropathological diagnostic criteria and develop gold standards for quality, safety and ethics standards for brain banking. BrainNet Europe also contributes to research on rare diseases, such as: Pick''s disease or other rare forms of dementia, as well as to questions after the events in the aging brain. Anyone can be a donor - irrespective of disease of the central nervous system or not, because for research purposes, one does not only need tissue samples from ill donors, but also from healthy ones for comparison.

Proper citation: BrainNet Europe (RRID:SCR_004461) Copy   

•   Source: SciCrunch Registry

http://www.usidnet.org/

Research consortium to advance scientific research in the primary immune deficiency diseases (PIDD) and: * Assemble and maintain a registry of patients with primary immunodeficiency diseases to provide a minimum estimate of the prevalence of each disorder in the United States. Provide a comprehensive clinical picture of each disorder and act as a resource for clinical and laboratory research. * Establish a multifaceted mentoring program to introduce new investigators into the field and stimulate interest and research in primary immune deficiency diseases. * Establish an advisory/review committee to maintain a cell/DNA Repository of biologic material from well-characterized PIDD patients for the advancement of scientific research USIDNET operates a large database of patient information for your use. The purpose and scope of this project is to assemble and maintain a registry of residents with primary immunodeficiency diseases. The project was started with the Registry of U.S. Residents with Chronic Granulomatous Disease. Since then, the registry has been expanded and now collects data on all primary immunodeficiency disorders. The following are just a few of the diseases housed in the registry: Chronic Granulomatous Disease, Common Variable Immunodeficiency Disease, DiGeorge Anomaly, Hyper IgM Syndrome, Leukocyte Adhesion Defect, Severe Combined Immunodeficiency Disease, Wiskott-Aldrich Syndrome, X-Linked Agammaglobulinemia Physicians who would like to register their patients or access the registry are encouraged to contact Onika Davis or Lamar Hamilton, USIDNET team, at odavis (at) primaryimmune.org, or lhamilton (at) primaryimmune.org

Proper citation: USIDNET: US Immunodeficiency Network (RRID:SCR_004672) Copy   

•   Source: SciCrunch Registry

http://caintegrator-info.nci.nih.gov/rembrandt

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on April 28,2023. REMBRANDT is a data repository containing diverse types of molecular research and clinical trials data related to brain cancers, including gliomas, along with a wide variety of web-based analysis tools that readily facilitate the understanding of critical correlations among the different data types. REMBRANDT aims to be the access portal for a national molecular, genetic, and clinical database of several thousand primary brain tumors that is fully open and accessible to all investigators (including intramural and extramural researchers), as well as the public at-large. The main focus is to molecularly characterize a large number of adult and pediatric primary brain tumors and to correlate those data with extensive retrospective and prospective clinical data. Specific data types hosted here are gene expression profiles, real time PCR assays, CGH and SNP array information, sequencing data, tissue array results and images, proteomic profiles, and patients'''' response to various treatments. Clinical trials'''' information and protocols are also accessible. The data can be downloaded as raw files containing all the information gathered through the primary experiments or can be mined using the informatics support provided. This comprehensive brain tumor data portal will allow for easy ad hoc querying across multiple domains, thus allowing physician-scientists to make the right decisions during patient treatments., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: Repository of molecular brain neoplasia data (RRID:SCR_004704) Copy   

•   Source: SciCrunch Registry

http://www.bioreclamationivt.com/

BioIVT, formerly BioreclamationIVT, is global provider of biological specimens and services. Provides biological and in vitro products specializing in control and disease state matrices manufactured from human and animal whole blood, plasma, serum, tissues and other fluids which are used in drug discovery, compound development, clinical and research diagnostics., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: Bioreclamation (RRID:SCR_004728) Copy   

•   Source: SciCrunch Registry

http://www.capitalbiosciences.com/

Biological products including Cell Immortalization Products, Clinically Defined Human Tissue, cDNA ORF Clones, Premade Adenoviruses, Purified Proteins, Viral Expression Systems and others as well as services like Custom Recombinant Adenovirus Production, Custom Recombinant Lentivirus Production, Protein Detection and Quantification and Stable Cell Line Production for academic and governmental research institutes, pharmaceutical and biotechnology industry. Capital Biosciences offers most types of human tissues, normal and diseased, with extensive clinical history and follow up information. Standard specimen format: Snap-frozen(flash-frozen), Formalin fixed and paraffin embedded (FFPE) tissues, Blood and blood products, Bone marrow, Total RNA, Genomic DNA, Total Proteins, Primary cell cultures, Viable frozen tissue. Tumor tissue samples include: Bladder cancer, Glioblastoma, Medulloblastoma, Breast Carcinoma, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Head and Neck (H&N) Carcinoma, Hepatocellular Carcinoma (HCC), Hodgkin's lymphoma, Kidney, Renal Cell Carcinoma, Lung Cancer, Non-Small Cell (NCSLC), Lung Cancer, Small Cell (SCLC), Melanoma, Mesothelioma, non-Hodgkin's Lymphoma, Ovarian Adenocarcinoma, Pancreatic Cancer, Prostate Cancer, Stomach Cancer.

Proper citation: Capital Biosciences (RRID:SCR_004879) Copy   

•   Source: SciCrunch Registry